TRAVERE THERAPEUTICS, INC. Restructuring Charges
TRAVERE THERAPEUTICS, INC. (TVTX) reported Restructuring Charges of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-02-19
- TRAVERE THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. restructuring charges for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. restructuring charges for fiscal 2024 was $2.44M, a 78.60% decline from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. restructuring charges for fiscal 2023 was $11.39M.
- TRAVERE THERAPEUTICS, INC. restructuring charges for fiscal 2022 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | $1.40M derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $1.40M derived: sum of 3 quarters · filed 2026-02-19 | $1.53M derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | $1.40M derived: sum of 2 quarters · filed 2026-02-19 | $1.53M derived: sum of 3 quarters · filed 2026-02-19 | $2.18M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.53M derived: sum of 2 quarters · filed 2026-02-19 | $2.18M derived: sum of 3 quarters · filed 2026-02-19 | $2.44M 10-K · filed 2026-02-19 |
| 2024-09-30 | $123.00K 10-Q · filed 2025-10-30 | $776.00K derived: sum of 2 quarters · filed 2025-10-30 | $1.03M 10-Q · filed 2025-10-30 | $12.43M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $653.00K 10-Q · filed 2025-08-06 | $912.00K 10-Q · filed 2025-08-06 | $12.31M derived: sum of 3 quarters · filed 2026-02-19 | $12.31M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $259.00K 10-Q · filed 2025-05-01 | $11.65M derived: sum of 2 quarters · filed 2026-02-19 | $11.65M derived: sum of 3 quarters · filed 2026-02-19 | $11.65M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $11.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $11.39M derived: sum of 2 quarters · filed 2026-02-19 | $11.39M derived: sum of 3 quarters · filed 2026-02-19 | $11.39M 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 10-Q · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-21 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-20 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | -$242.00K 10-K · filed 2021-03-01 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-01 | -$242.00K 10-Q · filed 2018-11-01 | ||
| 2017-12-31 | $997.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $2.13M derived: sum of 2 quarters · filed 2020-02-24 | $3.11M derived: sum of 3 quarters · filed 2020-02-24 | $3.61M 10-K · filed 2020-02-24 |
| 2017-09-30 | $1.13M 10-Q · filed 2018-11-01 | $2.11M derived: sum of 2 quarters · filed 2018-11-01 | $2.61M 10-Q · filed 2018-11-01 | $3.02M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $981.00K 10-Q · filed 2017-11-07 | $1.48M derived: sum of 2 quarters · filed 2017-11-07 | $1.89M derived: sum of 3 quarters · filed 2019-02-26 | $2.29M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $498.00K 10-Q · filed 2017-11-07 | $910.00K derived: sum of 2 quarters · filed 2019-02-26 | $1.31M derived: sum of 3 quarters · filed 2019-02-26 | |
| 2016-12-31 | $412.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $808.00K derived: sum of 2 quarters · filed 2019-02-26 | $893.00K 10-K · filed 2019-02-26 | |
| 2016-09-30 | $396.00K 10-Q · filed 2017-11-07 | $481.00K 10-Q · filed 2017-11-07 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-07-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |